@ScripMandy

I am Managing Editor, US Commercial News, for the Citeline Commercial publication Scrip. Views expressed here are strictly my own.

 San Diego, CA
scrip.citeline.com
Joined May 2012
  • Tweets17.7K
  • Following747
  • Followers5.6K
360Media
$GILD Paying PepStar Therapeutics $1.275bn up front for a Phase I oral IL-23 inhibitor.
Gilead Sciences
@GileadSciences7h
#GileadNews: Today, we announced an agreement to acquire an investigational oral peptide IL-23 receptor inhibitor program. Learn more: gilead.inc/4yFW5vM
1
2
404
Mandy Jackson retweeted
Renaissance Capital@IPOtweetOct 20
Allergy and autoimmune biotech Lycia Therapeutics sets terms for $250 million IPO $LYCA $IPO #IPO zpr.io/5mgVNLgN9d3G

Allergy and autoimmune biotech Lycia Therapeutics sets terms for $250 million IPO

Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, announced terms for its IPO on Tuesday.The South San Francisco, CA-based company plans to...

renaissancecapital.com
1
1
1,128
Mandy Jackson retweeted
Renaissance Capital@IPOtweetSep 25
siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range $ADRX $IPO #IPO zpr.io/PCejemsLJSwc

siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range

ADARx Pharmaceuticals, a Phase 3 biotech developing siRNA therapies for various diseases, raised $446 million by offering 26.3 million shares at $17, the high end of the $15 to $17 range.

renaissancecapital.com
2
3
2,578
This makes sense given $LLY’s past experience in bone health with Forteo and the potential for GLP-1 drugs to improve health for women with PCOS/PMOS.
Madison Muller@g0ingmadSep 10
Scoop: @EliLillyandCo has been laying the groundwork for a broader move into women’s health, assembling experts and hunting for new medicines across conditions including bone health and endometriosis. For @business: bloomberg.com/news/articles/…

Lilly’s GLP-1 Windfall to Fund Investments in Women’s Health

Eli Lilly & Co. has been laying the groundwork for a broader move into women’s health, assembling experts and hunting for new medicines across conditions including bone health and endometriosis,...

bloomberg.com
6
773
Mandy Jackson retweeted
Renaissance Capital@IPOtweetSep 10
SPAC Allarity Acquisition files for a $100 million IPO, targeting life sciences and biotech $ALLNU $IPO #IPO zpr.io/wVzhE3BJbr8k

SPAC Allarity Acquisition files for a $100 million IPO, targeting life sciences and biotech

Allarity Acquisition, a blank check company backed by Allarity Therapeutics targeting life sciences and biotech, filed on Thursday with the SEC to raise up to $100 million in an initial public...

renaissancecapital.com
1
1
4
2,327
Breaking FDA news from @PharmaPinkSheet
Sue Sutter@PinkSheetSutterSep 8
US FDA’s Davis, Mikhail Gain Permanent CDER, CBER Director Positions insights.citeline.com/pink-s…

US FDA Names Permanent CDER, CBER Directors, Creates AI Deputy Commissioner Post

Michael Davis and Karim Mikhail get permanent titles after months in acting roles, but their tenure may hinge on whether commissioner nominee Heidi Overton is confirmed and whether there are other...

insights.citeline.com
5
501
Interesting thoughts on $NVS $IONS Phase III failure for Lp(a) inhibitor pelacarsen (Scrip story coming soon)
Ethan J. Weiss
@ethanjweissSep 4
Replying to @ethanjweiss
Also this could be 1) that this was the worst of the Lp(a) directed therapies or it could be 2) that showing an improvement in ASCVD risk by lowering Lp(a) in patients aggressively treated to very low LDLc levels is not possible or 3) genetics were wrong and liek HDL, Lp(a) is a risk marker and not a mediator
1
1
3
1,223
A quick take from me (subscription required) on the $NVS $IONS Phase III data for Lp(a) inhibitor pelacarsen. Perhaps more to come from the Scrip team after the Labor Day weekend. insights.citeline.com/scrip/…

Novartis’s Lp(a) Inhibitor Pelacarsen Fails Phase III Cardiovascular Outcomes Trial

The closely watched class of lipoprotein (a) inhibitors has the potential to be the next blockbuster class of cardiovascular disease drugs, but Novartis’s Ionis-partnered pelacarsen failed in Phase...

insights.citeline.com
285
Notable that none of these companies involved in today’s MFN deals with the Trump administration are members of the Midsized Biotech Alliance of America, formed to lobby on behalf of mid-sized drug makers on policy issues like MFN. midsizedbiotech.com/about/

About - MBAA

Who We Are – America’s Biotech Backbone MBAA was founded to represent and protect the interests of midsized biopharmaceutical innovators which is an essential segment of America’s life sciences...

midsizedbiotech.com
Maaisha Osman@MaaishaOAug 31
Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB signs MFN deals: whitehouse.gov/fact-sheets/2…

Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufact...

ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced nine new agreements with pharmaceutical manufacturers to

whitehouse.gov
1
6
771
$RVMD Rasonque (Daraxonrasib) approved in the US and already available for prescribing to metastatic pancreatic cancer patients in the second line (and in 1L if not candidates for multiagent systemic therapy) at monthly WAC price of $39,800. revmed.com/media/news/13366/…

Media - Revolution Medicines

At Revolution Medicines our mission is to revolutionize treatment for patients with RAS-addicted cancers through the discovery, development and delivery of innovative, targeted medicines.

revmed.com
1
2
515
Jefferies said in a note this morning that they expected $35,000/month while an investor survey showed expectations of $41,800. $RVMD
268
Spreading fast. We see and smell smoke out here in La Mesa/El Cajon area. Stay safe everyone!
San Diego County Air Pollution Control District
@sdapcdAug 17
***ACTIVE SMOKE ADVISORY*** INCIDENT: Sorrento Fire AFFECTED AREA: Central San Diego County AFFECTED COMMUNITIES: Mira Mesa, Miramar, Tierrasanta, areas around Mission Trails Regional Park, College Area For more information visit, sdapcd.org/air-quality/smoke… #SorrentoFire
2
512
$REPL Replimune wins US FDA accelerated approval for Tudriqev (vusolimogene oderparepvec) for advanced cutaneous melanoma
U.S. FDA
@FDAAug 6
Today, FDA granted approval to a genetically modified oncolytic viral therapy for adults with resistant advanced melanoma. This approval underscores FDA’s commitment to using every available regulatory tool to help bring meaningful treatment options to patients with serious diseases. fda.gov/news-events/press-an…
Image with a green background displaying the FDA logo. Text reads, "Biologic Approval. FDA approves engineered viral immunotherapy for patients with treatment‑resistant advanced Melanoma." There are illustrations of medical items like bottles and a syringe.

ALT Image with a green background displaying the FDA logo. Text reads, "Biologic Approval. FDA approves engineered viral immunotherapy for patients with treatment‑resistant advanced Melanoma." There are illustrations of medical items like bottles and a syringe.

2
642
Mandy Jackson retweeted
Renaissance Capital@IPOtweetAug 6
Cardiovascular diseases biotech Braveheart Bio prices upsized IPO at $18, above the range $BRVE $IPO #IPO zpr.io/vicRzHeAxzR4

Cardiovascular diseases biotech Braveheart Bio prices upsized IPO at $18, above the range

Braveheart Bio, a Phase 3-ready biotech developing oral small molecules for cardiovascular diseases, raised $383 million by offering 21.3 million shares at $18, above the $15 to $17 range.

renaissancecapital.com
1
1
1,203
Takeda’s Orzeyful (oveporexton) approved for narcolepsy type 1
U.S. FDA
@FDAAug 5
For the first time, a medicine has been approved for narcolepsy type 1 as a complete disorder — targeting the biology behind it, not just its symptoms. Narcolepsy type 1 affects ~1 in 2,000 Americans and causes debilitating symptoms that touch every part of daily life. Today's approval means patients now have a therapy that addresses the full constellation of those symptoms. This treatment received both Breakthrough Therapy Designation and Priority Review — two FDA programs designed to bring transformative medicines to patients faster. fda.gov/news-events/press-an…
1
378
Mandy Jackson retweeted
Renaissance Capital@IPOtweetAug 5
Immune-focused biotech Attovia Therapeutics prices previously upsized IPO at $17, as expected $ATTO $IPO #IPO zpr.io/mvXbGPDhQBD2

Immune-focused biotech Attovia Therapeutics prices previously upsized IPO at $17, as expected

Attovia Therapeutics, a Phase 1 biotech developing biotherapeutics for immune-mediated diseases, raised $289 million by offering 17 million shares at $17, as expected.

renaissancecapital.com
1
2
1,436
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 29
Metabolic disorders biotech Vogenx sets terms for $75 million IPO $VOGX $IPO #IPO zpr.io/A9fsfXcJNdHJ

Metabolic disorders biotech Vogenx sets terms for $75 million IPO

Vogenx, a Phase 2b biotech developing therapies for endocrine and metabolic disorders, announced terms for its IPO on Wednesday.The Raleigh, NC-based company plans to raise $75 million by offering...

renaissancecapital.com
1
2
1,715
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 29
Phase 1 immune system diseases biotech Attovia Therapeutics sets terms for $200 million IPO $ATTO $IPO #IPO zpr.io/jyNnjBbUXVL8

Phase 1 immune system diseases biotech Attovia Therapeutics sets terms for $200 million IPO

Attovia Therapeutics, a Phase 1 biotech developing biotherapeutics for immune-mediated diseases, announced terms for its IPO on Wednesday.The San Carlos, CA-based company plans to raise $200 million...

renaissancecapital.com
1
3
1,495
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 27
Obstructive Sleep Apnea pharma Apnimed sets terms for $150 million IPO $APMD $IPO #IPO zpr.io/uZSJRczfJMDa

Obstructive Sleep Apnea pharma Apnimed sets terms for $150 million IPO

Apnimed, a late-stage drug developer advancing a pill for obstructive sleep apnea, announced terms for its IPO on Monday.The Cambridge, MA-based company plans to raise $150 million by offering 10...

renaissancecapital.com
1
3
1,310
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 17
Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO $LTGO $IPO #IPO zpr.io/bdDvEcRAbB2g

Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO

Latigo Biotherapeutics, a Phase 3-ready biotech developing non-opioid, oral therapies for acute and chronic pain, filed on Friday with the SEC to raise up to $100 million in an initial public...

renaissancecapital.com
1
1
3
1,978
Load more